Literature DB >> 17589762

Retreatment in leprosy: a case-control study.

Ricardo Arraes Alencar Ximenes1, Maria Eugênia Novinsk Gallo, Maria de Fátima de Medeiros Brito.   

Abstract

OBJECTIVE: To assess risk factors for retreatment of leprosy patients.
METHODS: A case-control study with patients from two reference care units in Recife, northeastern Brazil, in 2003. The case group included retreated patients (N=155) and the control group comprised those patients who were not retreated (N=155) matched by year of diagnosis and health care unit. Univariate and multivariate analyses were conducted to test the associations and odds ratios and related 95% confidence intervals were estimated.
RESULTS: The following factors were found to be significantly associated (p<0.05) with retreatment: occurrence of adverse immunological reactions after treatment completion (OR=2.3; 95% CI=1.18;4.83), final bacterial index > or = 1 (OR=6.43; 95% CI=1.67;24.74), therapeutic regimen consisting of sulfone monotherapy (OR=10; 95% CI=0.01;0.78) and reports of household contacts (OR=2.2; 95% CI=0.24;0.85).
CONCLUSIONS: The study findings reinforce that the use of dapsone monotherapy should be discontinued, and highlight the need for epidemiological monitoring of specific groups of leprosy patients after treatment completion through periodical clinical and laboratory evaluation. Further studies to explore the association between final bacterial index and retreatment are strongly recommended.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17589762     DOI: 10.1590/s0034-89102006005000037

Source DB:  PubMed          Journal:  Rev Saude Publica        ISSN: 0034-8910            Impact factor:   2.106


  1 in total

1.  Atypical lesions in relapsed leprosy.

Authors:  Theisla Kely Azevedo Raiol; Solange Emanuelle Volpato; Patrícia de Barros Guimarães; Maria Luciana Andrade de Almeida Lopes; Daniela Mayumi Takano; Jaci Maria Santana
Journal:  An Bras Dermatol       Date:  2014 Sep-Oct       Impact factor: 1.896

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.